



Our Mission: To drive efforts to cure psoriatic disease and improve the lives of those affected.

National Psoriasis Foundation Applauds the Biosimilars Action Plan

The National Psoriasis Foundation applauds the release of the Food and Drug Administration's new [Biosimilars Action Plan](#). The introduction of biologic therapies transformed care for many of the more than 8 million Americans who live with psoriatic disease. Building upon those advancements, we remain optimistic of the promise of biosimilars to increase access and provide even greater choice of therapies for our patient community.

We appreciate the FDA's commitment to advancing innovation and improving competition while maintaining a strong focus on patient safety. This Biosimilars Action Plan has the potential to facilitate a more robust commercial market for biosimilars and we applaud the FDA for using the full suite of policy and scientific levers at its disposal to advance patient care.

We are especially encouraged to see the continued commitment to patient and provider education and look forward to partnering with the FDA on these efforts. We also welcome the creation of the Office of Therapeutic Biologics and Biosimilars and welcome the opportunity to engage with the office to provide the psoriatic disease patient perspective on the innovation of biosimilars.

We appreciate the leadership of Dr. Scott Gottlieb and the staff at the FDA on this issue. We look forward to working with all interested stakeholders to ensure that patients are kept at the center of the plan's implementation.